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Abstract 22 
New chemotherapeutic agents with novel mechanisms of action are in urgent need to combat the 23 
tuberculosis pandemic.  A library of twelve C8-linked pyrrolo[2,1-c][1,4]benzodiazepine(PBD)-24 
heterocyclic polyamide conjugates (1-12) was evaluated for anti-tubercular activity and DNA sequence 25 
selectivity.  The PBD-conjugates were screened against slow-growing Mycobacterium bovis BCG and 26 
M. tuberculosis H37Rv and fast-growing Escherichia coli, Pseudomonas putida and Rhodococcus sp. 27 
RHA1 bacteria.  DNase I footprinting and DNA thermal denaturation experiments were used to 28 
determine the molecules’ DNA recognition properties.  The PBD-conjugates were highly selective for 29 
the mycobacterial strains and exhibited significant growth inhibitory activity against the pathogenic M. 30 
tuberculosis H37Rv, with compound 4 showing MIC values (MIC = 0.08 mg/L) similar to those of 31 
rifampin and isoniazid.  DNase I footprinting results showed that the PBD-conjugates with three 32 
heterocyclic moieties had enhanced sequence selectivity and produced larger footprints with distinct 33 
cleavage patterns compared to the two-heterocyclic chain PBD-conjugates.  DNA melting experiments 34 
indicated a covalent binding of the PBD-conjugates to two AT-rich DNA-duplexes containing either a 35 
central GGATCC or GTATAC sequence and showed that the polyamide chains affect the interactions 36 
of the molecules with DNA.  The PBD-C8-conjugates tested in this study have a remarkable anti-37 
mycobacterial activity and can be further developed as DNA-targeted anti-tubercular drugs. 38 
Keywords 39 
Drug discovery; DNA-minor groove binding agents; Pyrrolobenzodiazepines; Anti-tubercular agents; 40 
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1. Introduction 42 
Tuberculosis (TB) is a global health challenge, with 9 million new cases and 1.5 million deaths reported 43 
in 2013.1  Furthermore, it is estimated that one third of the world’s population is infected with 44 
Mycobacterium tuberculosis, accounting for a large reservoir of the bacilli.1  The increasing incidence 45 
of TB is also linked to the steady increase in multi-drug and extensively-drug resistant tuberculosis 46 
(MDR/XDR-TB) strains, which renders TB difficult to treat.1,2  Therefore, new antibiotics with novel 47 
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and pleiotropic modes of action are urgently needed to combat the TB pandemic, the rise of resistant 48 
bacilli and also provide new, safer and shorter drugs regimens.  To this end, the complete reconstruction 49 
of the M. tuberculosis regulatory network 3 has laid the foundation for the development of DNA-50 
targeted anti-mycobacterial agents.  The ability of DNA sequence-selective agents to target specific 51 
promoter regions of the M. tuberculosis DNA can be exploited to disrupt the binding of mycobacterial 52 
transcription factors, induce bacterial cell death, overcome antimicrobial resistance and maximize 53 
therapeutic efficacy. 54 
DNA-targeted chemotherapeutic agents are an important class of compounds, which have long attracted 55 
interest due to their distinctive mode of action involving specific interactions with predetermined DNA 56 
sequences.4-7  Among these agents, pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) have played a major 57 
role in cancer and antibacterial chemotherapy.8, 9  PBDs are a family of antitumour-antibiotics first 58 
isolated from cultures of Streptomyces species.10  These molecules are DNA sequence-selective agents 59 
that covalently bind, via their N10-C11 imine functionality, to the C2-amino groups of guanine residues 60 
within the minor groove of DNA, spanning three DNA base pairs with a preference for Pu–G–Pu (where 61 
Pu = purine; G = guanine) sequences (Figure 1).9, 11  PBD monomers block transcription by inhibiting 62 
RNA polymerase activity in a sequence-specific manner.12 63 
Since their discovery, several PBD analogues have been synthesised and extensively evaluated for their 64 
anticancer and antibacterial activities.8, 13-17  However, to our knowledge, there are only few studies 65 
focusing on the anti-mycobacterial activity of the PBDs.  Taylor and Thurston reported that PBD 66 
dimers, in which two PBD units are tethered through a C8/C8′′ diether linker to improve DNA-binding 67 
affinity and sequence specificity, exhibited notable activity against a panel of rapid and relatively rapid-68 
growing mycobacteria, Mycobacterium smegmatis, M. fortuitum, M. abscessus, M. phlei and M. 69 
aurum.18  Although showing anti-mycobacterial activity, the PBD dimers displayed significant 70 
cytotoxicity against human cell lines, especially compared to PBD monomers, and may be only used as 71 
“drug of last resort” to treat intractable infections caused by multi-drug resistant pathogens.19  In another 72 
study, Kamal et al. showed that PBD-5,11-diones (PBD dilactams) inhibited the growth of 73 
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Mycobacterium avium, M. intracellulare and M. tuberculosis.  PBD-dilactams stabilise duplex-DNA to 74 
a lesser extent than PBDs, as they lack the N10-C11 imine moiety responsible for the electrophilic 75 
alkylation of the C2-NH2 of guanine bases, thus resulting in a non-covalent DNA interaction and 76 
reduced antibacterial and anticancer potency.9, 20 77 
In the present study, we investigated the anti-mycobacterial activity and DNA binding properties of a 78 
library of twelve C8-linked PBD-heterocyclic polyamide conjugates (1-12) (Figure 2), which were 79 
previously shown to have strong in vitro anticancer activities. 21-23  The di- or tri-heterocyclic polyamide 80 
chains of 1-12 are comprised of combinations of pyrrole (Py), imidazole (Im) and thiazole (Th) rings 81 
known for their ability to modulate the ligands’ DNA-binding affinity.24  C8-linked PBD-polyamide 82 
conjugates, unlike PBD dilactams, retain the ability to form covalent DNA-adducts, characteristic 83 
responsible for their improved cancer cell cytotoxicity and antibacterial activities,15 and have a more 84 
favourable cytotoxicity profile compared to the PBD dimers.15,17   85 
PBD-conjugates 1-12 were screened against slow-growing Mycobacterium bovis BCG and M. 86 
tuberculosis H37Rv and fast-growing Escherichia coli, Pseudomonas putida and Rhodococcus sp. and 87 
minimum inhibitory concentration values (MIC) were determined.  Cytotoxicity against mouse 88 
macrophages RAW264.7 was also evaluated.  The DNaseI footprinting experiments and thermal 89 
denaturation assays were used to evaluate the DNA recognition properties of 1-12. 90 
2. Materials and methods 91 
C8-linked PBD-heterocyclic polyamide conjugates 92 
The twelve PBD-conjugates 1-12 were synthesised and purified using published synthetic routes21, 22 93 
and dissolved in DMSO prior to use.  94 
Microorganisms and mammalian cells 95 
Mycobacterium bovis BCG Pasteur (ATCC 35734) and M. tuberculosis H37Rv (ATCC 27294), and 96 
Escherichia coli K12 (ATCC 53323), Pseudomonas putida KT2442 (ATCC 47054) and Rhodococcus 97 
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sp. RHA1 were used to screen the antibacterial activity of the PBD conjugates.  Murine macrophages 98 
RAW264.7 (ATCC TIB71) were used in this study to evaluate the cytotoxicity of the PBD-conjugates. 99 
Mammalian macrophage cytotoxicity assay using resazurin assay 100 
The quantitation of eukaryotic cell toxicity was carried out as previously described.25  101 
Antibacterial assay against E. coli, P. putida and Rhodococcus sp.  102 
The evaluation of growth inhibition of the PDB-conjugates against E. coli, P. putida and Rhodococcus 103 
sp. was performed using the spot culture growth inhibition assay (SPOTi) in 24 well plates.26  A seed 104 
culture of each bacteria was prepared in Luria Bertani (LB) broth and grown overnight at 37 ºC with 105 
shaking at 200 rpm.  Rhodococcus sp. was grown in LB broth at 30 ºC with shaking at 200 rpm.  106 
Dilutions of the PBD-conjugates were performed in sterile DMSO at concentrations one thousand-fold 107 
more concentrated than the concentrations to be tested.  2 µL of each dilution were dispensed in each 108 
well of the 24 well plates, and 2 mL of LB agar were added to each well, and mixed.  2 µL of each 109 
inoculum containing approximately 105 colony-forming units (CFUs)/mL were carefully dispensed into 110 
the middle of the well on the surface of the solidified agar.  The plate was incubated overnight at 37 ºC 111 
for E. coli and P. putida, and at 30 ºC for Rhodococcus sp.  The plates were visually inspected and 112 
minimum inhibitory concentrations (MIC) values were recorded as the lowest concentration of PBD-113 
conjugates where no growth was observed.  Kanamycin was included as positive control. 114 
Anti-mycobacterial screening using HT-SPOTi 115 
M. bovis BCG and M. tuberculosis H37Rv were grown in Middlebrook 7H9 broth supplemented with 116 
0.02% (v/v) glycerol, 0.05% (v/v) tween-80 and 10% (v/v) albumin, dextrose and catalase (ADC; BD 117 
Biosciences) as a rolling culture at 2 rpm and 37 C, and as a stand culture at 37 C.  The 118 
antimycobacterial activities of the compounds were tested following the HT-SPOTi guidelines.26,27  HT-119 
SPOTi is a high-throughput growth inhibition assay conducted in a semi-automated 96 well plate 120 
format.  Compounds dissolved in DMSO at a final concentration of 50 mg/mL were serially diluted and 121 
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dispensed in a volume of 2 µL into each well of a 96 well plate to which 200 µL of Middlebrook 7H10 122 
agar medium kept at 55 C supplemented with 0.05% (v/v) glycerol and 10% (v/v) OADC was added.  123 
Wells with no compounds (DMSO only) and isoniazid (positive control) were used as experimental 124 
controls.  To all the plates, a drop (2 µL) of mycobacterial culture containing 2 × 103 CFUs was spotted 125 
in the middle of each well and the plates were incubated at 37 C for 7 days.  The MICs were determined 126 
as the lowest concentration of each compound where no mycobacterial growth was observed. 127 
DNase I footprinting assay 128 
Footprinting reactions were performed as previously described28 using the DNA fragments HexAfor 129 
and HexBRev, which together contain all 64 symmetrical hexanucleotide sequences.  The DNA 130 
fragments were obtained by cutting the parent plasmids with HindIII and SacI (HexA) or EcoRI and 131 
PstI (HexBRev) and were labelled at the 3’-end with [α-32P]dATP using reverse transcriptase.  After 132 
gel purification the radiolabelled DNA was dissolved in 10 mM Tris-HCl pH 7.5 containing 0.1 mM 133 
EDTA, at a concentration of about 10 c.p.s per µL as determined on a hand held Geiger counter.  1.5 134 
µL of radiolabelled DNA was mixed with 1.5 µL ligand that had been freshly diluted in 10 mM Tris-135 
HCl pH 7.5, containing 10 mM NaCl.  The complexes were left to equilibrate for at least 12 hours 136 
before digesting with 2 µL DNase I (final concentration about 0.01 units/ml).  The reactions were 137 
stopped after 1 minute by adding 4 µL of formamide containing 10 mM EDTA and bromophenol blue 138 
(0.1% w/v).  The samples were then heated at 100 °C for 3 minutes before loading onto 8% denaturing 139 
polyacrylamide gels containing 8 M urea.  Gels were fixed in 10% acetic acid, transferred to 3MM 140 
paper, dried and exposed to a phosphor screen overnight, before analysing with a typhoon 141 
phosporimager. 142 
DNA thermal denaturation studies 143 
Fluorescence melting curves were determined in a Roche LightCycler, using a total reaction volume of 144 
20 µL.  For each reaction the final oligonucleotide concentration was 0.25 µM, diluted in 10 mM sodium 145 
phosphate pH 7.4 containing 100 mM NaCl.  The experiments used the duplexes 5’-F-146 
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AAAAGGATCCAAAA/5’-TTTTGGATCCTTTT-Q and 5’-F-AAAAGTATACAAAA/5’-147 
TTTTGTATACTTTT-Q (F = fluorescein and Q = dabcyl).  In a typical experiment the samples were 148 
first denatured by heating to 95 °C at a rate of 0.1 °C s–1.  The samples were then maintained at 95 °C 149 
for 5 min before annealing by cooling to 25 °C at 0.1 °C s–1 (this is the slowest heating and cooling rate 150 
for the LightCycler).  They were held at 25 °C for a further 5 min and then melted by heating to 95 °C 151 
at 0.1 °C s–1.  Recordings of the fluorescence emission at 520 nm were taken during both the melting 152 
steps as well as during annealing.  The data were normalized to show the fractional change in 153 
fluorescence for each sample between the starting and final values.  Tm values were determined from 154 
the first derivatives of the melting profiles using the Roche LightCycler software. 155 
3. Results 156 
Growth inhibition of Mycobacterium spp.  157 
In Table 1 are illustrated the results of the anti-tubercular and anti-bacterial screening, the cytotoxicity 158 
evaluation and the selectivity index (SI) of 1-12.  Compounds 1-12 were tested for growth inhibition 159 
against two slow-growing mycobacteria, Mycobacterium bovis BCG and M. tuberculosis H37Rv.  The 160 
PBD-conjugates’ MIC values against M. tuberculosis ranged from 0.08 to 5.19 mg/L, whereas the MIC 161 
values against M. bovis ranged from 0.04 to 20 mg/L.  Dipyrrole-including PBD-conjugate 4 (Py-Py-162 
PBD) exhibited the highest growth inhibitory activity against M. tuberculosis with a MIC value of 0.08 163 
mg/L.  Compounds 5 (Py-Py-Im-PBD), 7 (Im-Im-Py-PBD), 9 (Py-Py-Th-PBD), 10 (Py-Th-Py-PBD) 164 
and 12 (Py-Py-Py-PBD) inhibited the growth of M. tuberculosis at 0.16 mg/L concentration.  PBD-165 
conjugate 1 (Py-Th-PBD) was active against M. tuberculosis and M. bovis at 0.31 and 0.16 mg/L, 166 
respectively, whereas compound 2 (Th-Py-PBD) inhibited the growth of both mycobacteria at 0.63 167 
mg/L.  Compounds 6 (Py-Im-Py-PBD) and 8 (Im-Im-Im-PBD) were found to be 60-fold more active 168 
against M. tuberculosis (0.32 mg/L) than M. bovis BCG (20 mg/L), whereas PBD-conjugates 7, 9 and 169 
10 were two-fold more active against M. bovis (0.08 mg/L) than M. tuberculosis (0.16 mg/L).  Pyrrole-170 
including PBD-conjugates 4 and 12 showed the highest growth inhibitory activity against M. bovis with 171 
a MIC of 0.04 mg/L.  On the other hand, thiazole-including PBD-conjugates 3 (Th-Th-PBD) and 11 172 
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(Th-Th-Th-PBD) exhibited the lowest growth inhibitory activity against both M. tuberculosis and M. 173 
bovis BCG with values of 5.19 and 20 mg/L, respectively.  First-line anti-tubercular drugs isoniazid and 174 
rifampin were used as positive controls and inhibited the growth of both mycobacterial strains at 0.05 175 
mg/L. 176 
Antibacterial activity on E. coli K12, P. putida KT2442 and Rhodococcus sp. RHA1 177 
In order to evaluate the mycobacterial specificity of PBD-conjugates 1-12 in whole cell experiments 178 
and determine whether the compounds selectively affected slow-growing mycobacteria in comparison 179 
with fast-growing bacteria, we investigated the growth inhibitory activities of 1-12 against Gram-180 
positive Rhodococcus sp. RHA1 and Gram-negative Escherichia coli K12 and Pseudomonas putida 181 
KT2442 bacteria.  The results in Table 1 show that the majority of PBD-conjugates (1, 4-7, 9, 10 and 182 
12) had a significant growth inhibitory activity against E. coli and Rhodococcus sp. with a MIC value 183 
of 1.25 mg/L.  Interestingly, PBD-conjugate 8 was 150-fold more active against M. tuberculosis (0.32 184 
mg/L) than Gram-negative E. coli and P. putida (>50 mg/L), whereas thiazole-containing PBD-185 
conjugates 3 and 11 were 10-fold more active against M. tuberculosis (5.19 mg/L) than E. coli, P. putida 186 
and Rhodococcus sp (>50 mg/L) strains.  Tri-pyrrole-including PBD-conjugate 12 was active against 187 
P. putida at 5 mg/L, whereas compounds 4 and 5 inhibited the growth of this bacterium at 10 mg/L.  188 
Compounds 7, 9 and 10 were found to be approximately 300-fold more active against M. tuberculosis 189 
(0.16 mg/L) than P. putida (50 mg/L).  The aminoglycoside antibiotic kanamycin was used as a positive 190 
control and inhibited the growth of E. coli and P. putida at 1.0 mg/L and Rhodococcus sp. at 10 mg/L.   191 
 192 
Macrophage RAW264.7 cytotoxicity 193 
The PBD-conjugates displayed various degrees of cytotoxicity against mammalian macrophages 194 
RAW264.7 with GIC50 values ranging from 1.66 to 4.45 mg/L.  The values of the Selectivity Index (SI), 195 
which is the ratio between macrophage half-growth inhibition concentration (GIC50) and MIC against 196 
the virulent H37Rv strain, ranged from 0.32 to 30.1, with PBD-conjugate 4 (Py-Py-PBD) exhibiting the 197 
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highest specificity (SI = 30.1) amongst the library members.  PBD-conjugates 5, 7, 9, 10 and 12 198 
exhibited a SI of 10.4, whereas 1 had a SI of 14.4.  Thiazole-including PBD-conjugates 3 and 11 showed 199 
the lowest specificity, with SI values of 0.46 and 0.32, respectively. 200 
DNase I footprinting 201 
DNase I footprinting was used to identify the binding sites of the PBD-conjugates, using the DNA 202 
fragments HexAfor and HexBrev,28 which together contain all 64 possible symmetrical hexanucleotide 203 
sequences.  The results are shown in Figure 3.  The left hand panels show the footprints with 10 µM of 204 
compounds 2, 3, 5, 7, 9 and 10 with HexAfor and HexBrev, while the two panels on the right show 205 
examples of the concentration dependence of the footprints with 5 and 9 on HexAfor.  It is evident that 206 
compounds 5, 9 and 10 produced large footprints in both HexAfor and HexBrev, while compound 7 207 
produced fewer footprints including two shorter footprints (4a and b) within site 4.  Each of these 208 
ligands produced a distinct cleavage pattern and the location of the major footprints is indicated in 209 
Figure 4.  All these compounds contain three rings conjugated to the PBD.  A few weaker footprints 210 
were seen with the compounds that only contain two conjugated rings.  Compound 2, which contains 211 
thiazole and pyrrole rings, produced footprints at sites 2, 4 and 8, while no footprints were seen with 3, 212 
which contains two thiazole rings.  It is clear that addition of the heterocycles affects the interaction of 213 
PBD with DNA.  PBD-conjugates 5 (Py-Py-Im-PBD), 9 (Py-Py-Th-PBD) and 10 (Py-Th-Py-PBD) 214 
bound to sites 1, 2, 3 and 4 within HexBrev, and to sites 6, 7, 8 and 9 within HexAfor, while the footprint 215 
at site 5 in HexBrev is only evident with compounds 5 and 9.  Compound 7 bound to fewer sites with 216 
clear footprints limited to sites 3, 4a and 4b on HexBrev and site 8 on HexAfor.  Although each ligand 217 
produced a characteristic cleavage pattern, it is noticeable that many of the footprints contained a short 218 
A/T tract followed by a guanine.  The two right hand panels of Figure 3 show the concentration 219 
dependence of the footprints with 5 and 9 on the HexAfor fragment.  At 5 µM concentration 5 produced 220 
a single footprint located in the lower part of site 8 within the sequence 5’-GCGCTTAAGTACT.  221 
Compound 9 produced footprints that persisted to lower concentrations, and the protections at the lower 222 
part of site 8 and in the centre of site 7 (5’-TAAACGTT) were still evident with 0.5 µM ligand. 223 
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DNA Melting Studies 224 
In order to further evaluate the contribution of the heterocyclic chains to the DNA recognition properties 225 
of the PBD-conjugates, the effects of the ligands on DNA-melting temperature were analysed using two 226 
fluorescently-labelled 14-mer DNA duplexes.  These AT-rich DNA duplexes contained either a central 227 
GGATCC or GTATAC and the results with 0.5 µM ligand are shown in Figure 5.  It can be seen that 228 
all four of these ligands stabilised the duplexes and produced transitions at elevated temperatures.  Since 229 
the ligands were covalently attached to the DNA, the Tm values of each transition did not change with 230 
the ligand concentration.  However, the relative proportions of the different components were altered, 231 
so that a greater fraction of the higher Tm was evident with higher ligand concentrations.  Each of these 232 
duplexes contains more than one guanine with which the conjugates could attach (two guanines for 233 
GTATAC and four for GGATCC) and further transitions were observed at higher ligand concentrations, 234 
as evident for 10 with both oligonucleotide duplexes.  At a concentration of 0.5 µM the ligand was in 235 
excess of the target duplex (0.25 µM).  The fraction of the melting transition that has shifted to the 236 
higher temperature therefore indicates the proportion of the duplex that has been modified within the 237 
incubation period, though the absolute values of the melting transitions indicate the stabilization that is 238 
imparted by the bound ligand.  The result of these experiments are summarised in Table 2.  It can be 239 
seen that there is a good correlation between the large footprints produced by PBD-conjugates 9 and 10 240 
with their greatest effect on the melting curves.  At 0.5 µM 9 shifted the entire melting curve to a higher 241 
temperature with both GTATAC (Tm = 29) and GGATCC (Tm = 35) with a small amount of 242 
uncomplexed duplex (5 and 10%, respectively).  A similar effect is seen with 10 and GTATAC for 243 
which about 30% of the transition was shifted to an even higher temperature transition.  In contrast, a 244 
significant amount of uncomplexed duplex (25%) was still evident with 10 and GGATCC, even though 245 
about 20% of the transition corresponded to a higher transition that suggested binding of a second 246 
ligand.  The melting curves with 0.5 µM 5 and 7 contained a large amount of the transition that 247 
corresponded to the uncomplexed duplex.  5 and 7 had a similar effect on GGATCC, though a greater 248 
fraction of GTATAC was bound by 7. 249 
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4. Discussion 250 
The anti-mycobacterial evaluation of PBD-conjugates 1-12 revealed that these compounds have 251 
remarkable growth inhibitory activity against M. tuberculosis H37Rv.  The nature and the length of the 252 
polyamide chain attached to the PBD unit had a significant influence on the molecules’ anti-microbial 253 
activity and DNA-sequence selectivity.  The presence of pyrrole rings in the polyamide chains affected 254 
the overall anti-tubercular activity of the compounds.  The di-pyrrole-containing 4 had a MIC value of 255 
0.08 mg/L, which was comparable to those of isoniazid and rifampin, and an encouraging therapeutic 256 
window (SI = 30) that could be further improved in the second generation of PBD-based anti-257 
tuberculosis agents.  Although displaying some degrees of cytotoxicity towards mammalian cells, PBD-258 
conjugate 4 represents a promising anti-TB therapeutic lead, particularly in light of the results generated 259 
by the large TB drug discovery campaign recently conducted by GlaxoSmithKline (GSK).29  260 
Researchers at GSK screened a 2 million proprietary-compounds collection for anti-mycobacterial 261 
activity against M. tuberculosis H37Rv and for cytotoxicity against mammalian cells (HepG2).  A set 262 
of 177 bioactive-leads were identified displaying MIC <10 µM against H37Rv and selectivity 263 
(therapeutic) index (SI = HepG2IC50/MIC) ≥50. These values are of the same order of magnitude of 264 
those displayed by 4 (MIC = 0.13 µM and SI = 30), thus qualifying this compound as a promising lead 265 
that can be improved in subsequent medicinal chemistry work. 266 
In addition, compounds 5, 7, 9, 10 and 12, which exhibited the second best growth inhibitory activity 267 
of the series against the TB causing bacillus (MIC = 0.16 mg/L), all contained at least one pyrrole ring 268 
in their three-heterocyclic chains.  PBD-conjugates with three-imidazole (8) and three-thiazole (11) 269 
chains showed a 2-fold and 30-fold decrease in M. tuberculosis growth inhibitory activity, respectively.  270 
This study also showed that the antimicrobial activity of PBD-conjugates 1-12 was highly selective 271 
against slow-growing mycobacteria M. tuberculosis and M. bovis compared to fast-growing bacteria E. 272 
coli, P. putida and Rhodococcus sp.  The mechanism of action of the PBDs is unique and involves the 273 
covalent binding to guanine residues within the DNA minor-groove.  The DNase I footprinting results 274 
showed that the PBD-conjugates bound with high affinity to large DNA sequences containing short A/T 275 
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stretches followed by a guanine residue, with 9 protecting the 5’-TAAACGTT sequence at a 276 
concentration as low as 0.5 µM.  This can be exploited to target discrete DNA sequences within the 277 
GC-rich mycobacterial genome and ultimately disrupt key enzymes and transcription factors.  DNA 278 
melting studies revealed that thiazole-containing 9, and to a lesser extent 10, formed strong complexes 279 
and markedly shifted the melting curves of the two 14-mer DNA duplexes used in this study, thus 280 
confirming the significant DNA stabilisation properties of the compounds.  In summary, these results 281 
show that 1-12 could serve as DNA-targeted therapeutic leads for the treatment of tuberculosis and 282 
further studies are underway to implement the potency and therapeutic index of these compounds. 283 
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Figure Legends 373 
 374 
Figure 1.  Schematic representation of the mechanism of action of PBDs involving the nucleophilic 375 
attack of the C2-NH2 group of a guanine residue to the N10-C11 imine moiety of PBD within the DNA 376 
minor groove.  377 
 378 
Figure 2. The library of twelve C8-linked PBD-heterocyclic polyamide conjugates 1-12 tested in this 379 
study. 380 
 381 
Figure 3.  DNase I footprinting patterns of the PBD-conjugates on the HexBrev and HexAfor DNA 382 
fragments.  The first two panels show the results in the presence of 10 µM of each of the PBD-383 
conjugates.  The second two panels show the concentration dependence of footprints on HexAfor with 384 
5 and 9.  Ligand concentrations (µM) are shown above each gel lane.  The bars indicate the location of 385 
clear footprints.  Tracks labelled GA are sequence markers specific for G and A, while con indicates 386 
DNase I cleavage in the absence of added ligand. 387 
 388 
Figure 4.  Sequences of HexAfor and HexBrev indicating the location of binding sites of the PBD-389 
conjugates (underlined and numbered in sequences).   390 
 391 
Figure 5.  Fluorescence melting profiles for the DNA duplexes 5’-F-AAAAGGATCCAAAA/5’-392 
TTTTGGATCCTTTT-Q and 5’-F-AAAAGTATACAAAA/5’-TTTTGTATACTTTT-Q (F = 393 
fluorescein and Q = dabcyl).  The ligand concentration was 0.5 µM with 0.25 µM target duplex. 394 
 395 
 396 
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 404 
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Figure 3 422 
 423 
 424 
 425 
 426 
 427 
Figure 4 428 
 429 
 430 
 431 
 432 
 433 
HexBrev  
5’-…GGATCCATGCATTAATTCGAATATTGATCATGACGTCGACATGTACATATGTATATACG 
                                                                 1                                                        2 
 
CGCGTACGCGTATACGTAGCGCGCTTATAAGCTTGCAATTGCCGGCTAATTAGGGCCCTC 
                                   3                                          4a                                         4b 
 
GAGCTCGCGATCGGCCGGATCC-3’  
                       5 
 
HexAfor 
5’-…GGATCCCGGGATATCGATATATGGCGCCAAATTTAGCTATAGATCTAGAATTCCGGACC 
                                                                                                     6 
 
GCGGTTTAAACGTTAACCGGTACCTAGGCCTGCAGCTGCGCATGCTAGCGCTTAAGTACTAG 
                                          7                                                                                   8 
 
TGCACGTGGCCATGGATCC-3’ 
                                      9 
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Figure 5 434 
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Tables 462 
 463 
Table 1.  Biological activity of PBD-conjugates 1-12. 464 
aThe SI was calculated by dividing the GIC50 for RAW264.7 by the MIC against M. tuberculosis H37Rv 465 
 466 
 467 
 468 
Table 2. Changes in melting temperature (Tm) of the oligonucleotide duplexes in the presence of 0.5 µM of each ligand and 469 
the fraction of the transition that corresponds to the uncomplexed duplex. 470 
 GGATCC 
Tm = 41.7 °C 
GTATAC 
Tm = 36.4 °C 
Tm % free Tm % free 
Py-Py-Im-PBD (5) 33 75 28 80 
Im-Im-Py-PBD (7) 30 80 28 55 
Py-Py-Th-PBD (9) 35 10 29 5 
  Py-Th-Py-PBD (10) 31 25 26 0 
 471 
 472 
473 
Compound 
MICs 
(mg/L) 
GIC50 
RAW264.7 
(mg/L) 
SIa 
Mycobacterium 
tuberculosis 
H37Rv 
Mycobacterium 
bovis BCG 
Escherichia 
coli K12 
Pseudomonas 
putida  
KT2442 
Rhodococcus 
sp. RHA1 
Py-Th-PBD (1) 0.31 0.16 1.25 >20 1.25 4.45 14.4 
Th-Py-PBD (2) 0.63 0.63 2.5 >50 5.0 2.41 3.83 
Th-Th-PBD (3) 5.19 <20 >50 >50 >50 2.41 0.46 
Py-Py-PBD (4) 0.08 0.04 1.25 10.0 1.25 2.41 30.1 
Py-Py-Im-PBD (5) 0.16 0.16 1.25 10.0 1.25 1.66 10.4 
Py-Im-Py-PBD (6) 0.32 <20 1.25 50.0 1.25 1.66 5.19 
Im-Im-Py-PBD (7) 0.16 0.08 1.25 >50 1.25 1.66 10.4 
Im-Im-Im-PBD (8) 0.32 <20 50.0 >50 10.0 1.66 5.19 
Py-Py-Th-PBD (9) 0.16 0.08 1.25 50.0 1.25 1.66 10.4 
Py-Th-Py-PBD (10) 0.16 0.08 1.25 >50 1.25 1.66 10.4 
Th-Th-Th-PBD (11) 5.19 ND >50 >50 >50 1.66 0.32 
Py-Py-Py-PBD (12) 0.16 0.04 1.25 5.0 1.25 1.66 10.4 
Isoniazid 0.05 0.05 ND ND ND 3000 60000 
Rifampin 0.05 0.05 ND ND ND 700 14000 
Kanamycin ND ND 1.0 1.0 10.0 ND ND 
 20 
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